Ulobetasol lotion - Valeant Pharmaceuticals

Drug Profile

Ulobetasol lotion - Valeant Pharmaceuticals

Alternative Names: Halobetasol propionate - Valeant Pharmaceuticals; IDP-122

Latest Information Update: 23 Aug 2016

Price : $50

At a glance

  • Originator Valeant Pharmaceuticals International
  • Class Anti-inflammatories; Antiallergics; Corticosteroids; Small molecules
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis

Most Recent Events

  • 16 Mar 2017 Valeant Pharmaceuticals announces intention to submit application to regulatory body for Plaque psoriasis in 2017 (Valeant Pharmaceuticals pipeline, March 2017)
  • 01 Jun 2016 Valeant Pharmaceuticals initiates a phase II trial for Plaque psoriasis in USA (NCT02785185)
  • 26 Apr 2016 Valeant Pharmaceuticals plans a phase II trial for Plaque psoriasis in USA (NCT02785185)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top